乳腺癌脑转移=死亡通知书？治疗研究上新成果荣登柳叶刀！

长q受体（EGFR）/人黏膜生长q受体2（HER2）/人黏膜生长q受体4（HER4）酪氨酸激酶消除剂，是中所国首个原研EGFR/HER2/HER4凋亡泻药物。

2018年

芳基替尼凭借II期诊断研究工作图表获国家政府泻药监局（NMPA）由此可知状况下批复上市，是本体瘤领域中所国首个凭借II期诊断研究工作获由此可知状况下批复上市的技术创新泻药。

2019年

芳基替尼被确立国家政府社保，大大改善可及机能性和可负荷机能性。

2020年

芳基替尼凭借两项不可忽视III期研究工作（PHENIX、PHOEBE）结果给予国家政府泻药监局无论如何批复上市。

现今，芳基替尼还在进行包括胰腺癌、肺癌、胆道癌等多个瘤种的多项诊断研究工作，持续探索多种不同病症多种不同收尾的病人计划，教化更是多中所国病患。

责任编辑：胰腺癌互助君

封底相片来源：医学期刊.癌

参考文献：

[1] Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort,phase 2 trial. Lancet Oncol 2022; published online Jan 24. (21)00716-6.

[2] Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003. 97(12): 2972-7.

[3] Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist. 2007. 12(7): 766-73.

[4] Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011. 17(14): 4834-43.

[5] Olson EM, Najita JS, Sohl J, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013. 22(4): 525-31.

[6] Tanguturi S, Warren L. The Current and Evolving Role of Radiation Therapy for Central Nervous System Metastases from Breast Cancer. Curr Oncol Rep. 2019. 21(6): 50.

。